Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
NCT01534637 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2018-08-15
Summary
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer. Antiemetic drugs, such as aprepitant may help lessen or prevent nausea and vomiting in patients receiving chemotherapy and radiation therapy
Conditions
Interventions
- DRUG
-
aprepitant
Given PO
- DRUG
-
gemcitabine hydrochloride
Given IV
- DRUG
-
Given PO
- DRUG
-
Given IV
- PROCEDURE
-
radiation therapy
Undergo radiation therapy
- OTHER
-
questionnaire administration
Ancillary studies
- PROCEDURE
-
quality-of-life assessment
Ancillary studies
- PROCEDURE
-
nausea and vomiting therapy
Receive aprepitant
- PROCEDURE
-
management of therapy complications
Receive aprepitant
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - collaborator INDUSTRY
-
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
Arthur Blackstock · Wake Forest University Health Sciences
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-08-31
- Primary Completion
- 2009-12-31
- Completion
- 2012-08-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00003546 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
NCT00025168 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01032057 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
NCT00983268 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
NCT01959672 ·Status: COMPLETED ·Phase: PHASE2
-
A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer
NCT02863367 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
NCT00026403 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00057876 ·Status: COMPLETED ·Phase: PHASE3
-
Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT01017822 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
NCT00003216 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
NCT01130701 ·Status: WITHDRAWN ·Phase: PHASE2
-
Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00416507 ·Status: COMPLETED ·Phase: PHASE3
-
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
NCT01821612 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
NCT01068327 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy and Radiation Following Pancreatic Surgery
NCT00660270 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00003426 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649 ·Status: COMPLETED ·Phase: PHASE3
-
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
NCT03087591 ·Status: COMPLETED ·Phase: PHASE1
-
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
NCT04415385 ·Status: UNKNOWN ·Phase: PHASE2
-
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
NCT00064051 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer
NCT00960284 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
NCT01456585 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
NCT01851174 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00026130 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
NCT00020345 ·Status: COMPLETED ·Phase: PHASE2